Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma Export

@article{citeulike:4531664, abstract = {In this study, we analyzed the long-term outcome of a risk-adapted transplantation strategy for mantle cell lymphoma in 121 patients enrolled in sequential transplantation protocols. Notable developments over the 17-year study period were the addition of rituximab to chemotherapy and preparative regimens and the advent of nonmyeloablative allogeneic stem cell transplantation (NST). In the autologous transplantation group (n = 86), rituximab resulted in a marked improvement in progression-free survival for patients who received a transplant in their first remission (where a plateau emerged at 3-8 years) but did not change the outcomes for patients who received a transplant beyond their first remission. In the NST group, composed entirely of patients who received a transplant beyond their first remission, durable remissions also emerged in progression-free survival at 5 to 9 years. The major determinants of disease control after NST were the use of a peripheral blood stem cell graft and donor chimerism of at least 95\%, whereas the major determinant of death was immunosuppression for chronic graft-versus-host disease. Our results show that long-term disease-free survival in mantle cell lymphoma is possible after rituximab-containing autologous transplantation for patients in first remission and after NST for patients with relapsed or refractory disease. 10.1182/blood-2008-10-184200}, author = {Tam, Constantine S. and Bassett, Roland and Ledesma, Celina and Korbling, Martin and Alousi, Amin and Hosing, Chitra and Kebraei, Partow and Harrell, Robyn and Rondon, Gabriela and Giralt, Sergio A. and Anderlini, Paolo and Popat, Uday and Pro, Barbara and Samuels, Barry and Hagemeister, Frederick and Medeiros, Jeffrey L. and Champlin, Richard E. and Khouri, Issa F.}, citeulike-article-id = {4531664}, citeulike-linkout-0 = {http://dx.doi.org/10.1182/blood-2008-10-184200}, citeulike-linkout-1 = {http://bloodjournal.hematologylibrary.org/cgi/content/abstract/113/18/4144}, citeulike-linkout-2 = {http://view.ncbi.nlm.nih.gov/pubmed/19168784}, citeulike-linkout-3 = {http://www.hubmed.org/display.cgi?uids=19168784}, day = {30}, doi = {10.1182/blood-2008-10-184200}, journal = {Blood}, keywords = {mcl}, month = {April}, number = {18}, pages = {4144--4152}, posted-at = {2009-05-17 14:47:07}, priority = {2}, title = {Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma}, url = {http://dx.doi.org/10.1182/blood-2008-10-184200}, volume = {113}, year = {2009} }

TY - JOUR ID - citeulike:4531664 L3 - citeulike-article-id:4531664 N2 - In this study, we analyzed the long-term outcome of a risk-adapted transplantation strategy for mantle cell lymphoma in 121 patients enrolled in sequential transplantation protocols. Notable developments over the 17-year study period were the addition of rituximab to chemotherapy and preparative regimens and the advent of nonmyeloablative allogeneic stem cell transplantation (NST). In the autologous transplantation group (n = 86), rituximab resulted in a marked improvement in progression-free survival for patients who received a transplant in their first remission (where a plateau emerged at 3-8 years) but did not change the outcomes for patients who received a transplant beyond their first remission. In the NST group, composed entirely of patients who received a transplant beyond their first remission, durable remissions also emerged in progression-free survival at 5 to 9 years. The major determinants of disease control after NST were the use of a peripheral blood stem cell graft and donor chimerism of at least 95%, whereas the major determinant of death was immunosuppression for chronic graft-versus-host disease. Our results show that long-term disease-free survival in mantle cell lymphoma is possible after rituximab-containing autologous transplantation for patients in first remission and after NST for patients with relapsed or refractory disease. 10.1182/blood-2008-10-184200 IS - 18 JF - Blood EP - 4152 TI - Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma VL - 113 SP - 4144 KW - mcl AU - Tam, Constantine AU - Bassett, Roland AU - Ledesma, Celina AU - Korbling, Martin AU - Alousi, Amin AU - Hosing, Chitra AU - Kebraei, Partow AU - Harrell, Robyn AU - Rondon, Gabriela AU - Giralt, Sergio AU - Anderlini, Paolo AU - Popat, Uday AU - Pro, Barbara AU - Samuels, Barry AU - Hagemeister, Frederick AU - Medeiros, Jeffrey AU - Champlin, Richard AU - Khouri, Issa PY - 2009/04/30/ UR - http://dx.doi.org/10.1182/blood-2008-10-184200 ER -